1. reported history or evidence of impaired liver or kidney function: gfr \<30 or bilirubin \>2x ult or inr \> 2x ult in the absence of anticoagulants 2. known hypersensitivity to zinc or resveratrol 3. diagnosis of covid-19 or sars-cov-2 infection \>4 days before enrollment 4. preexisting severe pulmonary disease requiring supplemental oxygen 5. clinically evident impairment of cognitive function, per physician discretion 6. active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. 7. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. 8. pregnant or lactating females. 9. coumadin treatment that can not be halted during the study period

1. reported history or evidence of impaired liver or kidney function: gfr \<30 or bilirubin \>2x ult or inr \> 2x ult in the absence of anticoagulants 2. known hypersensitivity to zinc or resveratrol 3. diagnosis of covid-19 or sars-cov-2 infection \>4 days before enrollment 4. preexisting severe pulmonary disease requiring supplemental oxygen 5. clinically evident impairment of cognitive function, per physician discretion 6. active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. 7. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. 8. pregnant or lactating females. 9. coumadin treatment that can not be halted during the study period

reported history or evidence of impaired liver or kidney function: gfr <30 or bilirubin >2x ult or inr > 2x ult in the absence of anticoagulants known hypersensitivity to zinc or resveratrol diagnosis of covid-19 or sars-cov-2 infection >4 days before enrollment preexisting severe pulmonary disease requiring supplemental oxygen clinically evident impairment of cognitive function, per physician discretion active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. pregnant or lactating females. coumadin treatment that can not be halted during the study period

reported history or evidence of impaired liver or kidney function: gfr <30 or bilirubin >2x ult or inr > 2x ult in the absence of anticoagulants known hypersensitivity to zinc or resveratrol diagnosis of covid-19 or sars-cov-2 infection >4 days before enrollment preexisting severe pulmonary disease requiring supplemental oxygen clinically evident impairment of cognitive function, per physician discretion active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. pregnant or lactating females. coumadin treatment that can not be halted during the study period

1. reported history or evidence of impaired liver or kidney function: gfr <30 or bilirubin >2x ult or inr > 2x ult in the absence of anticoagulants 2. known hypersensitivity to zinc or resveratrol 3. diagnosis of covid-19 or sars-cov-2 infection >4 days before enrollment 4. preexisting severe pulmonary disease requiring supplemental oxygen 5. clinically evident impairment of cognitive function, per physician discretion 6. active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. 7. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. 8. pregnant or lactating females. 9. coumadin treatment that can not be halted during the study period

1. reported history or evidence of impaired liver or kidney function: gfr <30 or bilirubin >2x ult or inr > 2x ult in the absence of anticoagulants 2. known hypersensitivity to zinc or resveratrol 3. diagnosis of covid-19 or sars-cov-2 infection >4 days before enrollment 4. preexisting severe pulmonary disease requiring supplemental oxygen 5. clinically evident impairment of cognitive function, per physician discretion 6. active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion. 7. active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion. 8. pregnant or lactating females. 9. coumadin treatment that can not be halted during the study period